U.S. tariff of 15% on EU goods is all-inclusive
The 15% rate applies to all goods, except for steel, aluminium, the official said. Tariffs on pharmaceuticals and semiconductors are now zero, but if and when they rise as a result of the U.S. 232 investigations, the tariff will be no higher than 15% as well.
This 15% ceiling also applies to cars and car parts. There are no quotas or limits on cars and car parts.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
an hour ago
- Reuters
Novo Nordisk expands lawsuits against weight-loss drug compounders
Aug 5 (Reuters) - Danish drugmaker Novo Nordisk ( opens new tab said on Tuesday it has filed 14 new lawsuits in the United States against the sale of unapproved versions of semaglutide, the main ingredient in its popular weight-loss and diabetes drugs, Wegovy and Ozempic. The new lawsuits target pharmacies and telehealth companies producing compounded versions of semaglutide "under the fake guise of personalization", Novo said, without naming the companies. Shares of major telehealth firm Hims & Hers (HIMS.N), opens new tab extended losses to fall nearly 13% in afternoon trade. It had earlier reported weaker-than-expected quarterly revenue. A Reuters search of legal filings found some cases filed by Novo in California dated Aug. 4 but none regarding San Francisco-based Hims. Hims was not immediately available for comment. Compounders copy brand-name medicines that are in short supply by combining, mixing or altering drug ingredients to meet demand. These companies were briefly allowed to produce hundreds of thousands of compounded doses of Novo's obesity and diabetes drugs when the Food and Drug Administration said they were in short supply. When the agency later banned the sale of these copies, Hims and Hers shifted to creating versions of semaglutide in personalized doses not accessible through the branded manufacturers. Novo's lawsuits allege that telehealth providers violate state corporate practice of medicine laws by improperly influencing doctors' decisions and steering patients toward knockoff compounded "semaglutide" under the guise of personalized medicine. In reality, these are knockoffs that have not been approved as safe and effective and are often made with illicit foreign active pharmaceutical ingredients (API), Novo said. It did not immediately respond to a Reuters query on which companies were being named in the lawsuit.
Finextra
2 hours ago
- Finextra
AmEx forms partnership with restaurant POS firm Toast
American Express (NYSE: AXP) and Toast (NYSE: TOST) today announced a strategic, multi-year partnership, focused on powering more personalized hospitality experiences across the vast network of Resy, Tock, and Toast restaurant locations in the United States to create better dining experiences that drive more guests to restaurants. 0 This content is provided by an external author without editing by Finextra. It expresses the views and opinions of the author. The companies plan to build tools for restaurants to create more seamless and personalized hospitality experiences combining the power of Resy and Tock's guestbook capabilities and Toast's Digital Chits technology, which allows restaurant staff to easily view important customer information directly on Toast Go ® handhelds and POS terminals during service. In addition, both companies will explore opportunities to leverage Toast capabilities to offer differentiated benefits that enhance the guest and American Express® Card Member experience. This partnership also intends to give restaurants, wineries, cafes, and bars greater visibility by making their listings from Resy and Tock available on the Local by Toast app, alongside those using Toast Tables. The partnership builds on American Express' significant investments in dining to better serve restaurants, diners, and American Express Card Members and merchants. In 2024, American Express acquired dining technology platform Rooam to enable integrations with leading technology platforms, like Toast. The company also acquired reservation platform Tock, adding 7,000 new restaurants and other venues to the American Express Global Dining network, in addition to the 20,000 restaurants and venues available on Resy. Resy and Tock have continued to invest in innovation with the launches of the Resy Android app, Resy's Discover Tab, Notify Enhancements, and Guest Lifetime Value in the last year to help drive increased demand for restaurants. For over a decade, Toast has been the trusted partner for restaurants committed to excellence, striving to make every restaurant more successful and delivering intuitive, powerful solutions that truly make a difference. Recent Toast innovations underscore its commitment to empowering restaurants and superpowering hospitality. New features such as Digital Chits, Menu Upsells*, and Advertising* powered by ToastIQ, Toast's intelligence engine, provide restaurateurs with deeper insights into their operations, helping them make data-driven decisions to optimize efficiency and drive growth. 'Restaurants today deliver exceptional experiences with leaner teams and tighter margins, making intelligent, connected tools more essential than ever,' said Pablo Rivero, SVP, American Express Global Dining and CEO, Resy and Tock. 'American Express and Toast together can help our partners deliver smarter service and more meaningful connections with their guests to drive both loyalty and growth.' "At Toast, we are dedicated to helping the restaurant community thrive. By bringing together two leading companies around a shared vision for enhancing the dining experience, this partnership lays the foundation for finding more ways for restaurants to better serve guests," said Aman Narang, CEO and Co-Founder at Toast. "Through this collaboration, Toast will look to provide our expansive network and innovative technology, empowering restaurants to reach diners and drive guest demand. Working together, we look forward to unlocking added visibility for restaurants and enabling more personalized service, leading to more memorable-–and repeat—visits.' 'Our Card Members spent over $87 billion on dining in the U.S. alone in 2024. This partnership is a natural evolution of our investment in this growing category,' said Alex Drummond, EVP and GM, American Express Membership Portfolio Services. 'As an industry-leading restaurant technology platform, we believe that Toast will seamlessly complement American Express' premium dining experiences and world class dining network to help usher in a new era of dining.' Product features are anticipated to start rolling out in 2026, with both companies looking to explore technology that will power richer, more personalized hospitality for guests and Card Members, and help restaurants fill their dining rooms with high-value diners. *Indicates early release features. To try them, customers can go to the Toast Test Kitchen on Toast Shop. The use of the term 'partner' or 'partnering' in this release does not mean or imply a formal legal partnership and is not meant in any way to alter the terms of the relationship between American Express and Toast or their relationships with any third parties.
BreakingNews.ie
4 hours ago
- BreakingNews.ie
Trump wants to initially impose 'small tariff' on pharma imports before rising to 150%
President Donald Trump said on Tuesday that the United States would initially place a "small tariff" on pharmaceutical imports before hiking it to 150 per cent within 18 months and eventually to 250 per cent in an effort to boost domestic production. "In one year, one-and-a-half years maximum, it's going to go to 150 per cent and then it's going to go to 250 per cent because we want pharmaceuticals made in our country," Trump told CNBC in an interview. Advertisement He did not specify the initial tariff rate on pharmaceuticals. Trump said last month that pharmaceutical tariffs could reach as high as 200 per cent. He said in February that sectoral tariffs on pharmaceuticals and semiconductor chips would start at "25 per cent or higher," rising substantially over the course of a year. Trump said on Tuesday that he plans to announce tariffs on semiconductors and chips in the "next week or so," but gave no further details. The United States has been conducting a national security review of the pharmaceutical sector, and the industry has been preparing for possible sector-specific tariffs. The administration has not announced when the results of that probe will be released. Several drugmakers have pledged multibillion-dollar investments in US manufacturing as Trump threatens import tariffs, with AstraZeneca recently committing $50 billion to expand its American operations. Advertisement PhRMA, the main lobbying group for the industry, did not immediately respond to a request for comment. Ireland Cork town nervous as Trump seeks to lure pharma in... Read More A framework agreement between the United States and the EU sets out that tariffs on pharmaceuticals and semiconductors are currently zero, but if the United States raises tariffs following its import investigation, they will be capped at 15 per cent. The pharmaceutical sector employs around 45,000 people in Ireland and is one of the country's major exports to the US. Total Irish exports were valued at €223.8 billion last year, with roughly one third going to the US. Of the €72.6 billion in US imports from Ireland, approximately €58 billion relates to pharmaceuticals and chemicals leaving Ireland.
